VINC

VINC
Healthcare — Biotechnology
Valhalla Score 46
A proprietary composite score from 0–100 measuring a stock's technical strength, sector-relative performance, and institutional flow activity. Higher scores indicate stronger setups.

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

📊 Key Statistics

Market Cap
P/E Ratio
EPS (TTM)
EPS YoY
Revenue YoY
Float
Short Float %
Inst. Ownership
Sector RS

📈 Fundamentals

ROE
ROIC
ROA
Current Ratio
Debt/Equity
Gross Margin
Net Margin
Dividend Yield
Next Earnings

Options Summary

Call OI
Put OI
P/C Ratio (OI)
Gamma Environment
Max Pain
Call Wall
Put Wall

🎯 Analyst Estimates

Consensus Target
High Target
Low Target
Analysts
Upside/Downside

📋 Quarterly Financials

Period Revenue Rev YoY EPS EPS YoY Gross Margin
Start Free Trial See full options flow, dark pool data & more

🔥 Recent Options Flow

TypeStrikeExpSizePremiumTime
Start Free Trial Institutional trades, dark pool vs lit exchange

🏛️ Institutional Trades

TypePriceSizeValueVenueTime
Start Free Trial Full insider & congressional trade history

👤 Insider Trades

NameTypeSharesPriceDate
Start Free Trial Top institutional holders & ownership data

🏦 Top Institutional Holders

InstitutionSharesValue% of Class

Start Your Free Trial

Have a referral code?

14-day free trial then $70/month. Cancel anytime.

Welcome to Valhalla